Professional Documents
Culture Documents
USPs:
Corporate Governance:
Business Model:
July 15
IPR compliance
Established relationship for over 5 years with pharma
giants in Custom synthesis
Focus on regulated (premium) markets (Europe/USA)
Manufacture API's for the Generics
Actively involved in developing alternate, patent noninfringing processes for APIs
Supplies advanced intermediates for generic APIs
Divis Laboratories
Share Movement
350,000
308,401
41% 41%
300,000
251,397
212,395
250,000
183,949
23%
200,000
18%
130,544
15%
150,000
100,000
50,000
-
120
115
110
105
100
95
90
85
80
S&P
Sales
Divis
43%
42%
41%
40% 40% 40%
39% 40%
39%
53,459 76,063 87,026110,276120,489 38%
37%
30%
20%
10%
0%
Sales Growth
300
30%
250
228.61
200
150
137.87
100
2010-11
July 15
40%
42%
EBITDA
50%
EBITDA Margin
163.85
22%
2012-13
ROA
24%
192.36
2011-12
28%
268.35
26%
2013-14
20%
2014-15
ROE
Divis Laboratories